埃博拉病毒 z-bo 2020-12-18 636

　　The top international academic journal "Science" published a research paper online by researcher Kartik Chandran of Einstein College of Medicine. The study proved that a two-pronged antibody can counter a unique immune escape mechanism, such as silks like Ebola. This kind of mechanism has been evolved by the virus.

　　 This is a crucial step on the road to the development of extensive protection against Ebola virus therapy. There is still an urgent need for such treatment. Filaviruses, including Ebola, have an unusual path into the host cell; they enter the cell through tiny transport vesicles (or endosomes), where they will be unique to a host cell called NPC1 The receptors interact and then take off the mask. In fact, this two-step pathway has a barrier effect: it allows the virus to be hidden in the immune system and hinders the efficacy of antiviral therapy. In order to find a way to defend against this evolving immune escape mechanism, Anna Wec and colleagues designed a bispecific antibody that can first bind to a specific glycoprotein (GP) outside the virus and ride its free ride ( Much like a Trojan horse), it can then attach to NPC1 in the endosome, preventing GP from binding to NPC1 and releasing Ebola virus into the host cell. In human cell lines, Wec et al. confirmed that these antibodies can neutralize the activity of all known Ebola viruses, proving that they have the potential to become a broad-spectrum anti-Ebola virus therapy. They also evaluated the efficacy of these antibodies in a mouse model. They found that, compared with the untreated control group, 70% of the mice survived 2 days after being infected with multiple lethal doses of Ebola virus. Come down. The author said that the bispecific antibody system has also been shown to resist other viral pathogens (such as Lassa virus) that are known to hijack intracellular receptors.